Prognostic Impact of Tumor Budding on Moroccan Gastric Cancer Patients.

IF 1.9 Q3 PATHOLOGY Clinical Pathology Pub Date : 2023-01-01 DOI:10.1177/2632010X231184329
Souhaila El Yaagoubi, Meryem Zaryouhi, Soumaya Benmaamar, Fatima El Agy, Layla Tahiri El Ousrouti, Nawal Hammas, Hicham El Bouhaddouti, Zineb Benbrahim, Nada Lahmidani, Laila Chbani
{"title":"Prognostic Impact of Tumor Budding on Moroccan Gastric Cancer Patients.","authors":"Souhaila El Yaagoubi,&nbsp;Meryem Zaryouhi,&nbsp;Soumaya Benmaamar,&nbsp;Fatima El Agy,&nbsp;Layla Tahiri El Ousrouti,&nbsp;Nawal Hammas,&nbsp;Hicham El Bouhaddouti,&nbsp;Zineb Benbrahim,&nbsp;Nada Lahmidani,&nbsp;Laila Chbani","doi":"10.1177/2632010X231184329","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumor budding (TB) has been defined as an independent prognostic factor in many carcinomas like colon adenocarcinoma, but its prognostic impact on gastric cancer patients remains not well established. In the present study, we aimed to highlight the correlation of tumor budding with clinicopathological features and predict its survival outcomes in gastric cancer patients for the first time in the Moroccan population.</p><p><strong>Methods: </strong>This study was conducted on 83 patients who underwent surgery for gastric adenocarcinoma from 2014 to 2020. The patient's clinico-pathological characteristics were obtained from the pathological and clinical records of each patient. Tumor budding was assessed on HES slides, according to the 2016 International Tumor Budding Consensus Conference criteria. The association of tumor budding grades with categorical and continuous variables were respectively assessed by the <i>χ</i>2-test and the unpaired <i>t</i>-test. Survival analysis was performed by the Kaplan-Meier method, the log-rank test.</p><p><strong>Results: </strong>Patients consisted of 65.1% of men and 34.9% of women with a median age of 61.2 years. Histologically, the majority of the tumors were adenocarcinoma (65.1%). Among all cases, 18.1% were classified as Bud1 (15/83), (27/83) 32.5% as Bud 2, and 49.4% (41/83) as Bud 3 grades. High-grade tumor budding (BUD 3) was found to be significantly associated with special clinicopathological features including older age (<i>P</i> = .02), unradical resection (R1/R2) (<i>P</i> = .03), and the presence of vascular invasion (<i>P</i> = .05), and perineural invasion (<i>P</i> = .04). Furthermore, tumors with high-grade tumor budding were significantly associated with a low rate of resected lymph nodes (<i>P</i> = .04) and advanced TNM stage (<i>P</i> = .02). Among all stages, high-grade tumor budding was correlated with shorter overall survival in univariate and multivariate analysis (<i>P</i> = .04). Patients with high-tumor budding had worse relapse-free survival compared with patients with low-tumor budding grade (<i>P</i> = .01).</p><p><strong>Conclusion: </strong>According to our study, the high-tumor budding grade was correlated with unfavorable clinicopathological features and poorer survival. The present study findings suggest that tumor budding should be considered in the treatment and prognosis of gastric cancer patients.</p>","PeriodicalId":53204,"journal":{"name":"Clinical Pathology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b3/b1/10.1177_2632010X231184329.PMC10326459.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2632010X231184329","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Tumor budding (TB) has been defined as an independent prognostic factor in many carcinomas like colon adenocarcinoma, but its prognostic impact on gastric cancer patients remains not well established. In the present study, we aimed to highlight the correlation of tumor budding with clinicopathological features and predict its survival outcomes in gastric cancer patients for the first time in the Moroccan population.

Methods: This study was conducted on 83 patients who underwent surgery for gastric adenocarcinoma from 2014 to 2020. The patient's clinico-pathological characteristics were obtained from the pathological and clinical records of each patient. Tumor budding was assessed on HES slides, according to the 2016 International Tumor Budding Consensus Conference criteria. The association of tumor budding grades with categorical and continuous variables were respectively assessed by the χ2-test and the unpaired t-test. Survival analysis was performed by the Kaplan-Meier method, the log-rank test.

Results: Patients consisted of 65.1% of men and 34.9% of women with a median age of 61.2 years. Histologically, the majority of the tumors were adenocarcinoma (65.1%). Among all cases, 18.1% were classified as Bud1 (15/83), (27/83) 32.5% as Bud 2, and 49.4% (41/83) as Bud 3 grades. High-grade tumor budding (BUD 3) was found to be significantly associated with special clinicopathological features including older age (P = .02), unradical resection (R1/R2) (P = .03), and the presence of vascular invasion (P = .05), and perineural invasion (P = .04). Furthermore, tumors with high-grade tumor budding were significantly associated with a low rate of resected lymph nodes (P = .04) and advanced TNM stage (P = .02). Among all stages, high-grade tumor budding was correlated with shorter overall survival in univariate and multivariate analysis (P = .04). Patients with high-tumor budding had worse relapse-free survival compared with patients with low-tumor budding grade (P = .01).

Conclusion: According to our study, the high-tumor budding grade was correlated with unfavorable clinicopathological features and poorer survival. The present study findings suggest that tumor budding should be considered in the treatment and prognosis of gastric cancer patients.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肿瘤出芽对摩洛哥胃癌患者预后的影响。
背景:肿瘤萌芽(Tumor芽肿,TB)已被定义为许多癌症(如结肠腺癌)的独立预后因素,但其对胃癌患者预后的影响尚不明确。在本研究中,我们旨在强调肿瘤萌芽与临床病理特征的相关性,并首次在摩洛哥人群中预测胃癌患者的生存结果。方法:对2014 - 2020年83例胃腺癌手术患者进行研究。从每位患者的病理和临床记录中获得患者的临床病理特征。根据2016年国际肿瘤出芽共识会议的标准,在HES玻片上评估肿瘤出芽。肿瘤出芽等级与分类变量和连续变量的相关性分别采用χ2检验和非配对t检验。生存分析采用Kaplan-Meier法,log-rank检验。结果:患者中男性占65.1%,女性占34.9%,中位年龄61.2岁。组织学上以腺癌居多(65.1%)。Bud1级为18.1% (15/83),bud2级为32.5% (27/83),bud3级为49.4%(41/83)。高级别肿瘤出芽(bud3)与特殊的临床病理特征显著相关,包括年龄(P = 0.02)、未根治切除(R1/R2) (P = 0.03)、血管侵犯(P = 0.05)和神经周围侵犯(P = 0.04)。此外,高度肿瘤出芽的肿瘤与低淋巴结切除率(P = 0.04)和TNM晚期(P = 0.02)显著相关。在所有分期中,单因素和多因素分析显示,高级别肿瘤出芽与较短的总生存期相关(P = 0.04)。高级别肿瘤出芽患者的无复发生存率较低级别肿瘤出芽患者差(P = 0.01)。结论:根据我们的研究,高肿瘤出芽分级与不利的临床病理特征和较差的生存有关。本研究结果提示,胃癌患者的治疗和预后应考虑肿瘤出芽。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Pathology
Clinical Pathology PATHOLOGY-
CiteScore
2.20
自引率
7.70%
发文量
66
期刊最新文献
Poroid Neoplasms: A Clinicopathological Study of 13 Cases. A Case of Cotyledonoid-Dissecting Leiomyoma - The Utility of Laparoscopic Biopsy and Gonadotropin-Releasing Hormone Analogs. Diagnosing B-cell acute lymphoblastic leukemia in 2 pediatric patients with recent SARS-CoV-2 infection. Primary Breast Lymphoma: A Case Report of a Common Tumor in an Uncommon Location. Clinical and Pathological Features of the Nested Subtype of Urothelial Carcinoma With Lymph Node Metastasis as the Initial Presentation: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1